Regulation (EC) No 273/2004 of the European Parliament and of the CouncilDangos y teitl llawn

Article 2 U.K. Definitions

For the purposes of this Regulation the following definitions shall apply:

(a)

‘[F1 scheduled substance’ means any substance listed in Annex I that can be used for the illicit manufacture of narcotic drugs or psychotropic substances, including mixtures and natural products containing such substances but excluding mixtures and natural products which contain scheduled substances and which are compounded in such a way that the scheduled substances cannot be easily used or extracted by readily applicable or economically viable means, [F2 medicinal products as defined in regulation 2 (medicinal products) of the Human Medicines Regulations 2012 and veterinary medicinal products as defined in regulation 2 of the Veterinary Medicines Regulations 2013 ];]

(b)

‘non-scheduled substance’ means any substance which, although not listed in Annex I, is identified as having been used for the illicit manufacture of narcotic drugs or psychotropic substances;

(c)

[F1 ‘placing on the market’ means any supply, whether in return for payment or free of charge, of scheduled substances in the [F3 United Kingdom]; or the storage, manufacture, production, processing, trade, distribution or brokering of these substances for the purpose of supply in the [F3 United Kingdom];]

(d)

‘operator’ means any natural or legal person engaged in the placing on the market of scheduled substances;

(e)

‘International Narcotics Control Board’ means the Board established by the Single Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol;

(f)

‘special licence’ means a licence that is granted to a particular type of operator;

(g)

‘special registration’ means a registration that is made for a particular type of operator[F1 ;]

(h)

[F4 ‘user’ means a natural or legal person other than an operator who possesses a scheduled substance and is engaged in the processing, formulation, consumption, storage, keeping, treatment, filling into containers, transfer from one container to another, mixing, transformation or any other utilisation of scheduled substances;

(i)

‘natural product’ means an organism or a part thereof, in any form, or any substances which occur in nature as defined in point 39 of Article 3 of Regulation (EC) No 1907/2006 of the European Parliament and of the Council(1).]

Textual Amendments

F1 Substituted by Regulation (EU) No 1258/2013 of the European Parliament and of the Council of 20 November 2013 amending Regulation (EC) No 273/2004 on drug precursors (Text with EEA relevance).

F2 Words in Art. 2(a) substituted (31.12.2020) by The Law Enforcement and Security (Amendment) (EU Exit) Regulations 2019 (S.I. 2019/742), regs. 1, 13(3)(a); 2020 c. 1, Sch. 5 para. 1(1)

F3 Words in Art. 2(c) substituted (31.12.2020) by The Law Enforcement and Security (Amendment) (EU Exit) Regulations 2019 (S.I. 2019/742), regs. 1, 13(3)(b); 2020 c. 1, Sch. 5 para. 1(1)

F4 Inserted by Regulation (EU) No 1258/2013 of the European Parliament and of the Council of 20 November 2013 amending Regulation (EC) No 273/2004 on drug precursors (Text with EEA relevance).

(1)

[F4 Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC ( OJ L 396, 30.12.2006, p. 1 ).]

Textual Amendments

F4 Inserted by Regulation (EU) No 1258/2013 of the European Parliament and of the Council of 20 November 2013 amending Regulation (EC) No 273/2004 on drug precursors (Text with EEA relevance).